IV Route for Azacitidine In Myelodysplastic Syndromes
The FDA has approved a New Drug Application (NDA) supplement to add intravenous (IV) use as a new route of administration for azacitidine (Vidaza, Pharmion). This agent, which is indicated for the treatment of myelodys-plastic syndromes (MDS), may now be infused over a period of 10 to 40 minutes in a clinic or hospital setting.
IV dosing remains the same as in the previous subcutaneous formulation, 75 mg/m2 daily for seven days every four weeks.
On May 19, 2004, azacitidine became the first drug approved by the FDA for MDS.
tricor 160 mg
Because this medication is associated with neutropenia and thrombocytopenia, complete blood counts should be performed as needed to monitor responses and toxicity.
Caution is needed for patients with impaired renal function.
Women should not breast-feed while taking azacitidine.
